|
ENPP4 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 6.12460000048998E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.00360000000011E-05 |
| Normal-vs-Stage2 |
1.159140E-03 |
| Normal-vs-Stage3 |
1.6507000000221E-07 |
| Normal-vs-Stage4 |
2.05379999999034E-05 |
| Stage1-vs-Stage2 |
9.262200E-01 |
| Stage1-vs-Stage3 |
1.814960E-01 |
| Stage1-vs-Stage4 |
3.346800E-01 |
| Stage2-vs-Stage3 |
3.026600E-01 |
| Stage2-vs-Stage4 |
4.028600E-01 |
| Stage3-vs-Stage4 |
9.785600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
1.93610000032152E-07 |
| Normal-vs-AfricanAmerican |
1.261600E-01 |
| Normal-vs-Asian |
2.838300E-03 |
| Caucasian-vs-AfricanAmerican |
4.485900E-02 |
| Caucasian-vs-Asian |
2.920400E-01 |
| AfricanAmerican-vs-Asian |
3.084600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
1.89480000023501E-07 |
| Normal-vs-Female |
4.32279999995622E-06 |
| Male-vs-Female |
4.205000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.89459999999842E-05 |
| Normal-vs-Age(41-60Yrs) |
1.99010000001554E-06 |
| Normal-vs-Age(61-80Yrs) |
2.06579999999512E-05 |
| Normal-vs-Age(81-100Yrs) |
7.247900E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
5.031000E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
8.803800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
8.130000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.599200E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
6.518400E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
7.461000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
7.124300E-03 |
| Classical-VS-Follicular |
3.909200E-01 |
| Classical-VS-Other |
3.930000E-01 |
| Classical-VS-Normal |
4.54309999997626E-06 |
| Tall-VS-Follicular |
6.100600E-03 |
| Tall-VS-Other |
8.204800E-01 |
| Tall-VS-Normal |
6.17109999767607E-08 |
| Follicular-VS-Other |
3.251000E-01 |
| Follicular-VS-Normal |
3.423200E-03 |
| Other-VS-Normal |
9.856700E-03 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.9744099999941E-05 |
| Normal-vs-N1 |
1.92229999995686E-06 |
| N0-vs-N1 |
2.630200E-01 |
|
|
